|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM).
|
31534192 |
2020 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GENESIS: Phase III trial evaluating BL-8040 + G-CSF to mobilize hematopoietic cells for autologous transplant in myeloma.
|
31495201 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, an intermediate dose of VP-16 with G-CSF appears to be an effective and tolerable chemo-mobilization method compared to CY and G-CSF, particularly in cases where use plerixafor in MM is difficult.
|
30642286 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The goal of this randomized, open-label, phase 3 trial was to compare the efficacy of chemomobilization using intermediate-dose cytarabine (ID-AraC) plus G-CSF with G-CSF alone in patients with MM referred for tandem autologous stem cell transplantation (autoSCT).
|
30266677 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.
|
30961974 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
|
30459429 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesized that administration of BTZ at peak G-CSF mobilization in patients with multiple myeloma (MM) would be safe, augment mobilization, and have an in vivo purging effect on circulating myeloma cells.
|
31358485 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study evaluated the correlation between the pharmacokinetics and pharmacodynamics of granulocyte colony-stimulating factor (lenograstim) and the impact of initiation time of apheresis on stem cell mobilization in patients with multiple myeloma.
|
30924165 |
2019 |
|
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There were no patients with MM cells in peripheral blood up to day 8 G-CSF administration in either treatment group.
|
30149148 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor in combination granulocyte-colony stimulating factor (G-CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
|
31363366 |
2019 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients.
|
29058701 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
|
29388164 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.
|
29410180 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We performed a retrospective analysis of patients with multiple myeloma who underwent autologous transplantation using granulocyte colony-stimulating factor (G-CSF)-mobilized non-cryopreserved grafts at our institution from January 1995 to December 2014.
|
30142418 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study focused on the efficacy of pegfilgrastim in PBSC mobilization compared with filgrastim exclusively after novel agent-based induction in a homogeneous group of MM patients.
|
29398647 |
2018 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is a phase 2 prospective randomized (1:1) open-label single-institution noninferiority study of tbo-filgrastim and filgrastim with plerixafor in patients with MM or NHL undergoing auto-HSCT.
|
28797783 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myeloma patients after induction treatment with bortezomib and dexamethasone.
|
28439700 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study.
|
29390394 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin's lymphoma and multiple myeloma.
|
27905003 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We retrospectively evaluated results of SC mobilization using either G-CSF alone or combined with high-dose cyclophosphamide (HD-CY) in MM patients after VCD induction.
|
28013359 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Outcomes were compared with historical matched controls during the same time period with multiple myeloma mobilized with G-CSF.
|
28675459 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plerixafor in combination with granulocyte-colony stimulating factor (G-CSF) is approved for autologous stem cell mobilization in poor mobilizing patients with multiple myeloma or malignant lymphoma.
|
27578390 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that P + G-CSF is highly efficient in MM patients and provides strong support for its upfront use in SC collection for MM patients.
|
27735212 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this retrospective study was to compare the mobilization efficiency of the three G-CSF variants originator filgrastim, lenograstim, and the biosimilar Filgrastim Hexal in a homogeneous group of multiple myeloma (MM) patients in first-line therapy.
|
28653421 |
2017 |
|
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, the efficacy of the biosimilar filgrastim Zarzio® combined with vinorelbine for chemo-mobilization of CD34+ hematopoietic progenitor cells (HPC) in patients with multiple myeloma has not been evaluated yet.
|
27001243 |
2017 |